Laboratory of Regenerative Immunotherapy, Department of Cell Growth and Differentiation, Center for iPS cell Research, Kyoto University, Sakyo-ku, Kyoto, Japan; Laboratory of Cancer Immunotherapy and Immunology, Transborder Medical Research Center, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan; Thyas Co. Ltd., Sakyo-ku, Kyoto, Japan.
Cell Stem Cell. 2022 Apr 7;29(4):493-495. doi: 10.1016/j.stem.2022.03.005.
Artificial thymic organoids (ATOs) allow the selective differentiation of chimeric antigen receptor (CAR)-transduced human iPSCs into CAR-T cells. In this issue of Cell Stem Cell, Wang et al. now use ATOs to produce human CD19 CAR-T cells that mimic conventional CAR-T cells and effectively control the progression of human CD19 leukemia in an animal model.
人工胸腺类器官（ATOs）可实现嵌合抗原受体（CAR）转导的人诱导多能干细胞（iPSCs）向 CAR-T 细胞的选择性分化。在本期《Cell Stem Cell》杂志上，Wang 等人现在使用 ATOs 生产出了模拟传统 CAR-T 细胞的人 CD19 CAR-T 细胞，并在动物模型中有效控制了人 CD19 白血病的进展。
Cell Stem Cell. 2022-4-7
J Immunother Cancer. 2023-12-22
Methods Mol Biol. 2019
Cancer Innov. 2023-12-17
Int J Mol Sci. 2024-2-26
Stem Cell Rev Rep. 2023-11
Front Bioeng Biotechnol. 2023-8-24
Biomark Res. 2023-5-6
Zotero 插件